
Finland · Medical devices startup
Cerenion Oy is a medical device company based in Oulu, Finland, founded in 2017.
Funding reportedLast round: Series A
Follow Cerenion Oy and see its new rounds in your feed.Start following
Cerenion Oy is a medical device company based in Oulu, Finland, founded in 2017.
The company specializes in AI-powered brain monitoring solutions tailored for acute healthcare and intensive care units (ICUs). Its primary product, C-Trend®, is an AI-assisted medical software that analyzes electroencephalography (EEG) data. This software integrates with standard EEG devices and patient monitors, providing real-time assessments of brain function to support clinical decision-making. Cerenion aims to make continuous EEG monitoring a standard practice in acute healthcare by simplifying complex brain data into clear metrics for medical professionals. The technology is clinically validated and patented, enhancing the quality and cost-effectiveness of intensive care. Cerenion serves medical professionals in critical care, particularly those managing patients recovering from cardiac arrest or at risk of seizures. The company holds over 20 patents and has raised approximately $7.27 million in funding to further develop its innovative brain monitoring technology.
Funding, as reported
From Cerenion Oy's own website: 2 founders, 6 on the team.
What they build
Known for
health caredigital healthqeegbrain health assessmentneuro monitoringmedical equipment manufacturinginformation technology & servicesce-markedquantitative eeg parametersneuroprognosispost-cardiac arrest eegbrain wave trendscritical care technologydelayed cerebral ischemiahospital & health careneurocritical care
Built with from their website
Yoast SEOGoogle Tag ManagerWordPress.orgAtlassianFont AwesomeElementorViewport MetaYoastCloudflare Rocket LoaderWordpress
Hello ElementorMicrosoft Exchange OnlinejQuery MigratePriority HintsimagesLoadedMicrosoft ExchangeNginxMicrosoft 365
Add your raise, your deck and your story, and put Cerenion Oy in front of investors. Or tell us what we have wrong.